Molecular Mechanisms of Fibrillin/LTBP Superfamily in Renal Fibrosis and Cardiorenal Syndrome

Molecular Mechanisms of Fibrillin/LTBP Superfamily in Renal Fibrosis and Cardiorenal

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05012228

Enrollment

Registered

2021-08-19

Start date

2021-07-01

Completion date

2024-12-31

Last updated

2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Fibrosis, CKD

Keywords

LTBP4

Brief summary

This project is to understand the LTBP4 expression in human renal fibrotic tissues. The investigators will exam major location of LTBP4 expression and check any similar or discrepancy in renal fibrosis with different etiologies.

Detailed description

The investigators will obtain the residual renal tissues with different etiologies and check the expression of LTBP4. The location and quantitation of LTBP4 in renal tissues will be checked. It will be great to understand the association between the severity of fibrosis and the expression of LTBP4 and other matrix proteins.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Abnormal kidney function, proteinuria, hematuria

Exclusion criteria

* N/A

Design outcomes

Primary

Measure	Time frame	Description
Expression of LTBP4 in human renal fibrotic tissue	5 years	—
Expression of biomarkers in human renal fibrotic tissue	5 years	Potential markers: eg. ROS-related proteins (8-oxodG, 4-HNE)

Countries

Taiwan

Contacts

Primary ContactChi-Ting Su, MD, MPH, PhD

A01218@ntucc.gov.tw+88697262878

Backup ContactYue-Jhu Huang, MS

yuejhuhuang@outlook.com+886912282113

Outcome results